Deerland Probiotics & Enzymes, the US-based supplier of science-backed solutions for microbiome health, has acquired Bifodan, a life science company specialised in developing, manufacturing and distributing the probiotic industry with unique product solutions as private label dietary supplements, medical devices and OTC drugs. Biofodan is based in Hundested, Denmark.
Effective with the acquisition, Bifodan is now a wholly-owned subsidiary of Deerland Probiotics & Enzymes, Inc.
Scott Ravech, CEO of Deerland, will continue in his role with global oversight of the newly combined company.
Bifodan’s current CEO, Steen Andersen, has been named President Deerland Probiotics and Enzymes International for the combined company. In this role, Andersen will be responsible for the Hundested site and all activities outside the Americas.
“We believe this investment will allow us to bring even greater value to our respective customers and to the enzyme and probiotic industries we serve,” Ravech said.
Deerland and Bifodan are both focused on providing innovative, scientifically-sound formulation and development services.
Commenting on the combined business, Andersen said: “We are excited to join the Deerland organisation and have great expectations to leverage the combined competencies of our companies to create a strong global player."
The acquisition of Bifodan gives Deerland a larger global footprint and highlights the company’s commitment to its vision for all people of all cultures to benefit from its enzyme, probiotic and prebiotic health products.
“Deerland and Bifodan are leaders in their respective markets. Bringing together this expertise will benefit both companies, our employees, and our customers,” Ravech concluded.